Citations

Clear

2416 citation(s) found for "Yu, Jason".

Radiosurgery and immune checkpoint inhibition in the treatment of brain metastases: A meta-analysis of patient-level data.
Lehrer, Eric J. , Peterson, Jennifer , Brown, Paul D. , Sheehan, Jason P. , Quiñones‐Hinojosa, Alfredo , Zaorsky, Nicholas G. , Trifiletti, Daniel M.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e14009-e14009

10.1200/jco.2018.36.15_suppl.e14009 Get It

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
Rhee, Frits van , Voorhees, Peter M. , Srkalović, Gordan , Ide, Makoto , Munshi, Nikhil C. , Schey, Stephen, Streetly, Matthew , Pierson, Sheila K. , Partridge, Helen , Shilling, Dustin, Stone, Katie , Greenway, Amy D, Ruth, Jason R., Lechowicz, Mary Jo , Jayanthan, Raj , Leitch, Heather A. , Pemmaraju, Naveen , Chadburn, Amy , Lim, Megan S. , Elenitoba‐Johnson, Kojo S.J. , Goodman, Aaron M. , Hoffmann, Christian , Zinzani, Pier Luigi , Ferrero, Simone , Terriou, Louis , Simpson, David , Rossi, Jean‐François, Yoshizaki, Kazuyuki , Oksenhendler, Éric , van Rhee, Frits , Wong, Raymond S M , Casper, Corey , Fajgenbaum, David C , Ferrero, Simone , Zinzani, Pier Luigi , Dispenzieri, Angela , Fosså, Alexander , Partridge, Helen L., Mukherjee, Sudipto , Chandrakasan, Shanmuganathan , Jaffe, Elaine S. , Krymskaya, Vera P. , Sato, Yasuharu , Wong, Raymond , Rossi, Jean‐François , Nasta, Sunita , Kurzrock, Razelle , Uldrick, Thomas S. , Casper, Corey , Fajgenbaum, David C. , Ide, Makoto , Lim, Megan S

Mayo Clinic

Blood | September 4, 2018 | Volume: 132 | Issue: 20 | Pages: 2115-2124

10.1182/blood-2018-07-862334 | PMID 30181172 Get It

Abstract Castleman disease (CD) describes a group of heterogeneous hematologic disorders with characteristic histopathological features. CD can present with unicentric or multicentric (MCD) regions of lymph node enlargement. Some cases of MCD are caused by human herpesvirus-8 (HHV-8), whereas others are HHV-8–negative/idiopathic (iMCD). Treatment of iMCD is challenging, and outcomes can be poor because no uniform treatment guidelines exist, few systematic studies have been conducted, and no agreed upon response criteria have been described. The purpose of this paper is to establish consensus, evidence-based treatment guidelines based on the severity of iMCD to improve outcomes. An international Working Group of 42 experts from 10 countries was convened by the Castleman Disease Collaborative Network to establish consensus guidelines for the management of iMCD based on published literature, review of treatment effectiveness for 344 cases, and expert opinion. The anti–interleukin-6 monoclonal antibody siltuximab (or tocilizumab, if siltuximab is not available) with or without corticosteroids is the preferred first-line therapy for iMCD. In the most severe cases, adjuvant combination chemotherapy is recommended. Additional agents are recommended, tailored by disease severity, as second- and third-line therapies for treatment failures. Response criteria were formulated to facilitate the evaluation of treatment failure or success. These guidelines should help treating physicians to stratify patients based on disease severity in order to select the best available therapeutic option. An international registry for patients with CD (ACCELERATE, #NCT02817997) was established in October 2016 to collect patient outcomes to increase the evidence base for selection of therapies in the future.
Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis
Moran, Sarah , Zgaga, Lina , Cuthbertson, David, Carette, Simon , Koening, Curry L. , Langford, Carol A. , McAlear, Carol A. , Moreland, Larry W. , Sreih, Antoine G. , Ytterberg, Steven R. , Little, Mark A. , Cuthbertson, David , Moreland, Larry W , Monach, Paul A. , Khalidi, Nader , Pagnoux, Christian , Seo, Philip , Specks, Ulrich , Wyse, Jason , Merkel, Peter A.

Mayo Clinic

Nephrology Dialysis Transplantation | September 1, 2018 | Volume: 35 | Issue: 2 | Pages: 283-291

10.1093/ndt/gfy300 | PMID 30380100 Get It

Abstract Background Prior work has shown that urinary soluble CD163 (usCD163) displays excellent biomarker characteristics for detection of active renal vasculitis using samples that included new diagnoses with highly active renal disease. This study focused on the use of usCD163 in the detection of the more clinically relevant state of mild renal flare and compared results of usCD163 testing directly to testing of urinary monocyte chemoattractant protein-1 (uMCP-1). Methods Patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV, n = 88) were identified within a serially sampled, longitudinal and multicentre cohort. Creatinine-normalized usCD163 and uMCP-1 levels were measured by enzyme-linked immunosorbent assay and, both alone and in combination, were compared between times of active renal AAV and during remission and/or active non-renal AAV. Results Samples from 320 study visits included times of active renal vasculitis (n = 39), remission (n = 233) and active extrarenal vasculitis (n = 48). Median creatinine levels were 0.9 mg/dL [interquartile range (IQR) 0.8–1.2] in remission and 1.4 mg/dL (IQR 1.0–1.8) during renal flare. usCD163 levels were higher in patients with active renal vasculitis compared with patients in remission and those with active extrarenal vasculitis, with median values of 162 ng/mmol (IQR 79–337), 44 (17–104) and 38 (7–76), respectively (P < 0.001). uMCP-1 levels were also higher in patients with active renal vasculitis compared with patients in remission and those with active extrarenal vasculitis, with median values of 10.6 pg/mmol (IQR 4.6–23.5), 4.1 (2.5–8.4) and 4.1 (1.9–6.8), respectively (P < 0.001). The proposed diagnostic cut-points for usCD163 and uMCP-1 were 72.9 ng/mmol and 10.0 pg/mmol, respectively. usCD163 and uMCP-1 levels were marginally correlated (r2 = 0.11, P < 0.001). Combining novel and existing biomarkers using recursive tree partitioning indicated that elevated usCD163 plus either elevated uMCP-1 or new/worse proteinuria improved the positive likelihood ratio (PLR) of active renal vasculitis to 19.2. Conclusion A combination of usCD163 and uMCP-1 measurements appears to be useful in identifying the diagnosis of subtle renal vasculitis flare.
Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation
Dukek, Brian A. , Kanipakam, Reddappa V.S.R., Ghoz, Hassan , Yab, Tracy C. , Giama, Nasra H., Onyirioha, Kristeen, Abdallah, Mohamed A., Burger, Kelli N. , Slettedahl, Seth W. , Smyrk, Thomas C. , Lewis, Jason T., Giakoumopoulos, Maria , Allawi, Hatim T. , Lidgard, Graham P. , Roberts, Lewis R. , Ahlquist, David A. , Kisiel, John B. , V S R Kanipakam, Reddappa, Ghoz, Hassan M, Berger, Calise K. , Foote, Patrick H. , Mahoney, Douglas W. , Roberts, Lewis R , Slettedahl, Seth W , Taylor, William R. , Abdallah, Mohamed A., Lewis, Jason T.

Mayo Clinic

Hepatology | August 31, 2018 | Volume: 69 | Issue: 3 | Pages: 1180-1192

10.1002/hep.30244 | PMID 30168613 Get It

Early detection improves hepatocellular carcinoma (HCC) outcomes, but better noninvasive surveillance tools are needed. We aimed to identify and validate methylated DNA markers (MDMs) for HCC detection. Reduced representation bisulfite sequencing was performed on DNA extracted from 18 HCC and 35 control tissues. Candidate MDMs were confirmed by quantitative methylation‐specific PCR in DNA from independent tissues (74 HCC, 29 controls). A phase I plasma pilot incorporated quantitative allele‐specific real‐time target and signal amplification assays on independent plasma‐extracted DNA from 21 HCC cases and 30 controls with cirrhosis. A phase II plasma study was then performed in 95 HCC cases, 51 controls with cirrhosis, and 98 healthy controls using target enrichment long‐probe quantitative amplified signal (TELQAS) assays. Recursive partitioning identified best MDM combinations. The entire MDM panel was statistically cross‐validated by randomly splitting the data 2:1 for training and testing. Random forest (rForest) regression models performed on the training set predicted disease status in the testing set; median areas under the receiver operating characteristics curve (AUCs; and 95% confidence interval [CI]) were reported after 500 iterations. In phase II, a six‐marker MDM panel (homeobox A1 [HOXA1], empty spiracles homeobox 1 [EMX1], AK055957 , endothelin‐converting enzyme 1 [ECE1], phosphofructokinase [PFKP], and C‐type lectin domain containing 11A [CLEC11A]) normalized by beta‐1,3‐galactosyltransferase 6 (B3GALT6) level yielded a best‐fit AUC of 0.96 (95% CI, 0.93‐0.99) with HCC sensitivity of 95% (88%‐98%) at specificity of 92% (86%‐96%). The panel detected 3 of 4 (75%) stage 0, 39 of 42 (93%) stage A, 13 of 14 (93%) stage B, 28 of 28 (100%) stage C, and 7 of 7 (100%) stage D HCCs. The AUC value for alpha‐fetoprotein (AFP) was 0.80 (0.74‐0.87) compared to 0.94 (0.9‐0.97) for the cross‐validated MDM panel (P < 0.0001). Conclusion : MDMs identified in this study proved to accurately detect HCC by plasma testing. Further optimization and clinical testing of this promising approach are indicated.
A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers
Zhang, Ming , Ferrari, Raffaele, Tartaglia, Maria Carmela , Keith, Julia , Surace, Ezequiel , Wolf, Uri, Sato, Christine , Grinberg, Mark, Liang, Yan , Xi, Zhengrui, Dupont, Kyle, McGoldrick, Philip, Weichert, Anna , McKeever, Paul M. , Schneider, Raphaël , McCorkindale, Michael D, Manzoni, Claudia , Rademakers, Rosa , Graff, Caroline , Parisi, Joseph E., Petersen, Ronald C., Miller, Bruce L. , Rooij, Jeroen van , Pijnenburg, Yolande A.L. , Zee, Julie van der, Broeckhoven, Christine Van , Ber, Isabelle Le , Deerlin, Vivianna Van, Suh, EunRan , Rohrer, Jonathan D. , Mead, Simon , Öijerstedt, Linn , Pickering‐Brown, Stuart , Rollinson, Sara, Rossi, Giacomina , Tagliavini, Fabrizio , Brooks, William S. , Dobson‐Stone, Carol , Halliday, Glenda M. , Hodges, John R. , Piguet, Olivier , Binetti, Giuliano , Benussi, Luisa , Ghidoni, Roberta , Sorbi, Sandro , Bruni, Amalia C. , Galimberti, Daniela , Rainero, Innocenzo , Rubino, Elisa , Lleó, Alberto, Ruiz, Agustı́n , Hernández, Isabel, Pástor, Pau , Díez-Fairén, Mónica , Borroni, Barbara , Pasquier, Florence , Deramecourt, Vincent , Lebouvier, Thibaud , Perneczky, Robert , Diehl‐Schmid, Janine , Huey, Edward D. , Mayeux, Richard , Nalls, Michael A., Hernandez, Dena G., Singleton, Andrew B., Momeni, Parastoo, Zeng, Zhen , Hardy, John , Zinman, Lorne , Nalls, Michael A., Ramasamy, Adaikalavan , Hodges, John R. , Bartley, Lauren, Hernández, Isabel, Boada, Merçé , Padovani, Alessandro , Cairns, Nigel J. , Serpente, María , Scarpini, Elio, Blesa, Rafael , ouml, Maria Landqvist Wald, Nilsson, Karin , Mackenzie, Ian R. , Hsiung, Ging‐Yuek Robin , Attems, Johannes , Pietrini, Pietro , Baborie, Atik, Jaros, Evelyn, Tierney, Michael C, Razquín, Cristina , Ortega‐Cubero, Sara , Alonso, Elena, Alexopoulos, Panagiotis , Kurz, Alexander , Pinessi, Lorenzo , Rogaeva, Ekaterina, Giaccone, Giorgio , Rowe, James B. , Uphill, James, Collinge, John, Danek, Adrian , Deerlin, Vivianna M Van, Grossman, Murray, Trojanowski, John Q. , Leber, Isabelle, Hannequin, Didier , Golfier, Véronique, Vercelletto, Martine, Brice, Alexis , Nacmias, Benedetta, Bagnoli, Silvia , Hjermind, Lena E. , Riemenschneider, Matthias, Mayhaus, Manuel, Ibach, Bernd, Gasparoni, Gilles, Pichler, Sabrina, Fox, Nick C. , Warren, Jason D. , Spillantini, Maria Grazia , Rizzu, Patrizia , Heutink, Peter , Snowden, Julie S. , Richardson, Anna , Maletta, Raffaele , Frangipane, Francesca, Bernardi, Livia , Conidi, Maria Elena, Smirne, Nicoletta , Rademakers, Rosa, Baker, Matt , Petersen, Ronald , Knopman, David, Josephs, Keith A. , Miller, Bruce L., Karydas, Anna M., Rosen, Howard J., Scheltens, Philip , Logroscino, Giancarlo , Capozzo, Rosa , Novelli, Valeria , Franceschi, M. , Postiglione, Alfredo, Milan, Graziella , Sorrentino, Paolo, Kristiansen, Mark, Chiang, Huei-Hsin, Rollin, Adeline, Deramecourt, Vincent, Kapogiannis, Dimitrios , Waldö, Maria Landqvist , Halliday, Glenda , Logroscino, Giancarlo , Rowe, James B , Hsiung, Gink-Yuek , Miller, Bruce L , Hardy, John , Scheltens, Philip , Rohrer, Jonathan D , Fox, Nick C , Padovani, Alessandro , Ruiz, Agustín , Pastor, Pau , Boada, Merce , Tartaglia, Maria Carmela , Pasquier, Florence , Brooks, William , McGoldrick, Philip , McCorkindale, Michael , Dickson, Dennis W. , Boeve, Bradley F. , Seeley, William W. , Swieten, John C. van , Zee, Julie van der , Deerlin, Vivianna M. Van , Nacmias, Benedetta , Scarpini, Elio , Clarimón, Jordi , Lleó, Alberto , Grafman, Jordan Henry , Robertson, Janice , Rogaeva, Ekaterina A. , Kwok, John B. , Schofield, Peter R. , Thompson, Elizabeth A. , Cruchaga, Carlos , Forloni, Gianluigi , Albani, Diego , Fenoglio, Chiara , Nilsson, Christer, Mann, David , Morris, Christopher M. , Griffiths, Timothy David , McKeith, Ian G. , Thomas, Alan , Wassermann, Eric M. , Tierney, Michael C, George‐Hyslop, Peter St , Schlachetzki, Johannes C. M. , Cappa, Stefano F. , Piaceri, Irene , Nielsen, Jørgen Erik , Riemenschneider, Markus J. , Gu, Wei , Rossor, Martin N. , Morris, Huw R. , Gerhard, Alexander , Cupidi, Chiara , Anfossi, Maria , Gallo, Maura , Dopper, Elise G.P. , Seelaar, Harro , Puca, Annibale Alessandro , Franceschi, Massimo, Chiang, Huei‐Hsin, Ferrucci, Luigi , Brice, Alexis , Rainero, Innocenzo , Galimberti, Daniela , Pijnenburg, Yolande A L , Lebouvier, Thibaud , Graff, Caroline , Borroni, Barbara

Mayo Clinic

Brain | August 31, 2018 | Volume: 141 | Issue: 10 | Pages: 2895-2907

10.1093/brain/awy238 | PMID 30252044 Get It

Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)
Üstün, Celalettin , Pullarkat, Sheeja T. , Yeung, Cecilia C.S. , Broesby‐Olsen, Sigurd , Ohgami, Robert S. , Kim, Young , Vestergaard, Hanne , Chen, Dong , Kluin, Philip M., Dolan, Michelle, Mrózek, Krzysztof , Czuchlewski, David R., Horny, Hans‐Peter, George, Tracy I. , Kristensen, Thomas Kielsgaard , Ku, Nam K., Yi, Cecilia Arana , Møller, Michael , Marcucci, Guido , Hilberink, Jacobien R. , Pullarkat, Vinod , Shanley, Ryan , Kohlschmidt, Jessica, Coulombe, Janie , Salhotra, Amandeep , Soma, Lori , Cho, Christina , Hoermann, Gregor , Nakamura, Ryo , Deeg, Joachim, Bloomfield, Clara D. , Weisdorf, Daniel J. , Litzow, Mark R. , Valent, Peter , Huls, Gerwin , Yeung, Cecilia , Baughn, Linda, Chen, Dong , Møller, Michael Boe , Weisdorf, Dan , George, Tracy I , Arana Yi, Cecilia , Valent, Peter , Morgan, Elizabeth A. , Moodie, Erica E. M. , Sperr, Wolfgang R. , Baughn, Linda B. , Schiefer, Ana-Iris , Linden, Michael A. , Akin, Cem , Gotlib, Jason , Hornick, Jason L. , Nakamura, Ryo, Perales, Miguel‐Angel , Borthakur, Gautam

Mayo Clinic

Cancer Medicine | August 17, 2018 | Volume: 7 | Issue: 9 | Pages: 4447-4455

10.1002/cam4.1733 | PMID 30117318 Get It

AbstractBackgroundAlthough the prognosis of core‐binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse.MethodsEleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22).ResultsComplete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median disease‐free (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyper‐ or hypodiploidy were included in a scoring system (named I‐CBFit). DFS rate at 2 years was 76% for patients with a low‐risk I‐CBFit score compared with 36% for those with a high‐risk I‐CBFit score (P < 0.0001). Low‐ vs high‐risk OS at 2 years was 89% vs 51% (P < 0.0001).ConclusionsI‐CBFit composed of readily available risk factors can be useful to tailor the therapy of patients, especially for whom alloHCT is not need in CR1 (ie, patients with a low‐risk I‐CBFit score).
Neuroimaging of Early Life Epilepsy
Coryell, Jason , Gaillard, William D. , Shellhaas, Renée A. , Wusthoff, Courtney J. , Keator, Cynthia, Sullivan, Joseph , Loddenkemper, Tobias , Chu, Catherine J. , Massey, Shavonne L. , Saneto, Russel P., Berg, Anne T. , Wirrell, Elaine C., Shellhaas, Renée A , Gaillard, William D , Loddenkemper, Tobias , Berg, Anne T , Chu, Catherine J , Coryell, Jason , Wusthoff, Courtney J , Grinspan, Zachary M. , Wirrell, Elaine , Knupp, Kelly G. , Patel, Anup D. , Novotny, Edward J.

Mayo Clinic

Pediatrics | August 8, 2018 | Volume: 142 | Issue: 3 | Pages: No page available

10.1542/peds.2018-0672 | PMID 30089657 Get It

OBJECTIVES: We assessed the adherence to neuroimaging guidelines and the diagnostically relevant yield of neuroimaging in newly presenting early life epilepsy (ELE). METHODS: There were 775 children with a new diagnosis of epilepsy (&lt;3 years old at onset) who were recruited through the ELE study at 17 US pediatric epilepsy centers (2012–2015) and managed prospectively for 1 year. The data were analyzed to assess the proportion of children who underwent neuroimaging, the type of neuroimaging, and abnormalities. RESULTS: Of 725 children (93.5%) with neuroimaging, 714 had an MRI (87% with seizure protocols) and 11 had computed tomography or ultrasound only. Etiologically relevant abnormalities were present in 290 individuals (40%) and included: an acquired injury in 97 (13.4%), malformations of cortical development in 56 (7.7%), and other diffuse disorders of brain development in 51 (7.0%). Neuroimaging was abnormal in 160 of 262 (61%) children with abnormal development at diagnosis versus 113 of 463 (24%) children with typical development. Neuroimaging abnormalities were most common in association with focal seizure semiology (40%), spasms (47%), or unclear semiology (42%). In children without spasms or focal semiology with typical development, 29 of 185 (16%) had imaging abnormalities. Pathogenic genetic variants were identified in 53 of 121 (44%) children with abnormal neuroimaging in whom genetic testing was performed. CONCLUSIONS: Structural abnormalities occur commonly in ELE, and adherence to neuroimaging guidelines is high at US pediatric epilepsy centers. These data support the universal adoption of imaging guidelines because the yield is substantially high, even in the lowest risk group.
Reduction of Hip Arthroscopy Post-Operative Pain Using Ultrasound-guided Fascia-Iliaca Block: A Prospective Randomized Control Trial
Glomset, John Larson, Kim, Eugene J. , Tokish, John M. , Renfro, Suzanne D., Seckel, Tyler B., Adams, Kyle J. , Folk, Jason, Kim, Eugene J.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | July 27, 2018 | Volume: 6 | Issue: 7_suppl4 | Pages: No page available

10.1177/2325967118s00149 Get It

Objectives: Ultrasound guided fascia-Iliaca blocks have been used for pain control following hip arthroscopy. There is little evidence regarding their effectiveness in comparison to other pain control modalities in hip arthroscopy patients. To compare efficacy of ultrasound guided fascia iliac block with intra-articular ropivacaine in controlling pain after hip arthroscopy. Methods: Between 2015 and 2017, 95 patients undergoing hip arthroscopy were randomly assigned to 2 groups. The first group received an ultrasound-guided fascia-iliaca block with 50-60mLs of 0.35% ropivacaine. The second group received intra-articular injection of 20 mL of 0.5% ropivacaine at the completion of the surgical case. Primary outcomes were post-operative pain scores in the recovery room, at PACU discharge, at 2 weeks, 6 weeks, and 3 months. Secondary outcomes included intraoperative and PACU narcotic usage (converted to morphine equivalent use) as well as readmission rates, PACU recovery time and postoperative nausea and vomiting (PONV). Results: Postoperative pain across all points did not significantly differ between the 2 groups. Intraoperative and PACU narcotics did not differ significantly between the 2 groups. Readmission rates, PACU recovery time and PONV did not significantly differ between the 2 groups. There were no associated complications in either group. Conclusion: Ultrasound guided fascia iliaca block for hip arthroscopy had no clinical advantage when compared to one time intra-articular ropivacaine injection. Furthermore, an intraarticular injection decreases costs and is a safe and more efficient modality for postoperative pain control following hip arthroscopy.